, Volume 11, Issue 3, pp 325–330 | Cite as

Acromegaly and anaplastic astrocytoma: coincidence or pathophysiological relation?

  • Alberto Fernandez
  • Niki Karavitaki
  • Olaf Ansorge
  • Violet Fazal-Sanderson
  • John A. H. Wass
Case Report


Insulin-like growth factor type I (IGF-I) is an important promoter in the tumorigenesis of several extracranial and intracranial neoplasms. In astrocytic-cell tumors, the role of autocrine and paracrine IGF-I expression in enhancing tumoral progression is well established. However, the influence of systemic IGF-I levels on the clinical behavior of astrocytic neoplasms remains an open subject of research. We report the case of a 28-year-old man who presented simultaneously with acromegaly and an anaplastic astrocytoma, which had rapidly progressed from a low-grade astrocytoma. The coexistence of systemic IGF-I hypersecretion with a quick progression in the histopathological grade of the astrocytoma raises the compelling question of whether the clinical behavior of the astrocytic tumor was influenced by the acromegalic status. The role of IGF-I signaling in the pathogenesis of astrocytic-cell tumors and the experience with therapeutic strategies addressing this pathway in astrocytomas are also discussed.


Acromegaly Astrocytoma IGF-I 


  1. 1.
    Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of liège, Belgium. J Clin Endocrinol Metab 91(12):4769–4775PubMedCrossRefGoogle Scholar
  2. 2.
    Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102–152PubMedCrossRefGoogle Scholar
  3. 3.
    Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21(3):215–244PubMedCrossRefGoogle Scholar
  4. 4.
    Jaques G, Rotsch M, Wegmann C, Worsch U, Maasberg M, Havemann K (1988) Production of immunoreactive insulin-like growth factor-I and response to exogenous IGF-I in small cell lung cancer cell lines. Exp Cell Res 176:336–343PubMedCrossRefGoogle Scholar
  5. 5.
    Yee D, Morales FR, Hamilton TC, Von Hoff DD (1991) Expression of insulin-like growth factor-I, its binding proteins, and its receptors in ovarian cancer. Cancer Res 51:5107–5112PubMedGoogle Scholar
  6. 6.
    Merrill MJ, Edwards NA (1990) Insulin-like growth factor-I receptors in human glial tumors. J Clin Endocrinol Metab 71:199–209PubMedCrossRefGoogle Scholar
  7. 7.
    Central brain tumor registry of the United States. Online access on Last access on September 4th 2007
  8. 8.
    Hirano H, Lopes MB, Laws ER Jr, Asakura T, Goto M, Carpenter JE, Karns LR, VandenBerg SR (1999) Insulin-like-growth-factor-1 content and pattern of expression correlates closely with histopathologic grade in diffusely infiltrating astrocytomas. Neuro-Oncol 1(2):109–119PubMedCrossRefGoogle Scholar
  9. 9.
    Kleihues P, Burger PC, Scheithauer BW (1993) The new WHO classification of brain tumors. Brain Pathol 3:255–268PubMedCrossRefGoogle Scholar
  10. 10.
    Recht LD, Lew R, Smith TW (1992) Suspected low-grade glioma: Is deferring treatment safe? Ann Neurol 31(4):431–436PubMedCrossRefGoogle Scholar
  11. 11.
    McCormack BM, Miller DC, Budzilovich GH Voorhees GJ, Ransohoff J (1992) Treatment and survival of low-grade astrocytoma in adults—1977–1988. Neurosurgery 31(4):636–642PubMedCrossRefGoogle Scholar
  12. 12.
    Pignatti F, Van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084PubMedCrossRefGoogle Scholar
  13. 13.
    Schiffer D, Cavalla P, Chio A, Richiardi P, Giordana MT (1997) Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol 34:31–35PubMedCrossRefGoogle Scholar
  14. 14.
    Russo VC, Gluckman PD, Feldman EL, Werther GA (2005) The insulin-like growth factor system and its pleiotropic functions in the brain. Endocr Rev 26(7):916–943PubMedCrossRefGoogle Scholar
  15. 15.
    Anderson MF, Aberg MA, Nilsson M, Eriksson PS (2002) Insulin-like growth factor-I and neurogenesis in the adult mammalian brain. Brain Res Dev Brain Res 134:115–22PubMedCrossRefGoogle Scholar
  16. 16.
    Torres-Aleman I (1999) Insulin-like growth factors as mediators of functional plasticity in the adult brain. Horm Metab Res 31:114–119PubMedCrossRefGoogle Scholar
  17. 17.
    Friend KE, Khandwala HM, Flyvbjerg A, Hill H, Li J, McCutcheon IE (2001) Growth hormone and insulin-like growth factor-I: effects on the growth of glioma cell lines. Growth Horm IGF Res 11:84–91PubMedCrossRefGoogle Scholar
  18. 18.
    Brockmann MA, Ulbricht U, Gruner K, Fillbrandt R, Westphal M, Lamszus K (2003) Glioblastoma and cerebral microvascular endothelial cell migration in response to tumor-associated growth factors. Neurosurgery 52:1391–1399PubMedCrossRefGoogle Scholar
  19. 19.
    Glick RP, Lichtor T, Unterman TG (1997) Insulin-like growth factors in central nervous system tumors. J Neurooncol 35:315–325PubMedCrossRefGoogle Scholar
  20. 20.
    Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R (1994) Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-I (IGF-I) receptor are non-tumorigenic and induce regression of wild-type tumors. Cancer Res 54:2218–2222PubMedGoogle Scholar
  21. 21.
    Seely BL, Samimi G, Webster NJ (2002) Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells in-vivo. BMC Cancer 2:15PubMedCrossRefGoogle Scholar
  22. 22.
    Schneider HJ, Pagotto U, Stalla GK (2003) Central effects of the somatotropic system. Eur J Endocrinol 149(5):377–92PubMedCrossRefGoogle Scholar
  23. 23.
    Busiguina S, Fernandez AM, Barrios V, Clark R, Tolbert DL, Berciano J, Torres-Aleman I (2000) Neurodegeneration is associated to changes in serum insulin-like growth factors. Neurobiol Dis 7:657–665PubMedCrossRefGoogle Scholar
  24. 24.
    Connors MH, Boggan JE, Chong B, Kollipara S (1996) Expansion and shrinkage of central nervous system tumor coinciding with human growth hormone therapy: case report. Neurosurgery 39(6):1243–1246PubMedCrossRefGoogle Scholar
  25. 25.
    Simmons NE, Laws ER (1998) Glioma occurrence after sellar irradiation: case report and review. Neurosurgery 42(1):172–178PubMedCrossRefGoogle Scholar
  26. 26.
    Renehan AG, O’Dwyer ST, Shalet SM (2001) Screening colonoscopy for acromegaly in perspective. Clin Endocrinol (Oxf) 55:731–733CrossRefGoogle Scholar
  27. 27.
    Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. The Lancet 363(9418):1346–1353CrossRefGoogle Scholar
  28. 28.
    Swerdlow AJ, Reddingius RE, Higgins CD, Spoudeas HA, Phipps K, Qiao Z, Ryder WDJ, Brada M, Hayward RD, Brook CGD, Hindmarsh PC, Shalet SM (2000) Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab 85:4444–4449PubMedCrossRefGoogle Scholar
  29. 29.
    Sklar CA, Mertens AC, Mitby P, Occhiogrosso G, Qin J, Heller G, Yasui Y, Robison LL (2002) Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 87:3136–3141PubMedCrossRefGoogle Scholar
  30. 30.
    Reubi JC, Lang W, Maurer R, Koper JW, Lamberts SW (1987) Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res 47:5758–5764PubMedGoogle Scholar
  31. 31.
    Mawrin C, Schulz S, Pauli SU, Treuheit T, Diete S, Dietzmann K, Firsching R, Schulz S, Hollt V (2004) Differential expression of sst1, sst2a and sst3 somatostatin receptor expression proteins in low-grade and high-grade astrocytomas. J Neuropathol Exp Neurol 63(1):13–19PubMedGoogle Scholar
  32. 32.
    Merlo A, Hausmann O, Wasner M, Steiner P, Otte A, Jermann E, Freitag P, Reubi JC, Muller-Brand J, Gratzl O, Macke HR (1999) Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 5:1025–1033PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Alberto Fernandez
    • 1
  • Niki Karavitaki
    • 1
  • Olaf Ansorge
    • 2
  • Violet Fazal-Sanderson
    • 1
  • John A. H. Wass
    • 1
  1. 1.Endocrinology Department, Oxford Centre for Diabetes, Endocrinology and MetabolismChurchill HospitalOxfordUK
  2. 2.Neuropathology DepartmentThe John Radcliffe HospitalOxfordUK

Personalised recommendations